Login to Your Account

First Phase III Data

Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain

By Trista Morrison

Monday, December 14, 2009
Roche subsidiary Genentech Inc. and Biogen Idec Inc. said their first Phase III trial with anti-CD20 antibody ocrelizumab achieved its primary endpoint of improving ACR20 scores in rheumatoid arthritis patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription